Equities analysts expect that Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) will post earnings per share of ($1.97) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Biohaven Pharmaceutical’s earnings, with estimates ranging from ($2.36) to ($1.60). Biohaven Pharmaceutical reported earnings of ($1.34) per share during the same quarter last year, which indicates a negative year over year growth rate of 47%. The business is expected to announce its next quarterly earnings results on Thursday, February 27th.
On average, analysts expect that Biohaven Pharmaceutical will report full year earnings of ($9.88) per share for the current financial year, with EPS estimates ranging from ($10.40) to ($8.83). For the next year, analysts anticipate that the business will post earnings of ($6.78) per share, with EPS estimates ranging from ($8.71) to ($5.12). Zacks’ EPS calculations are an average based on a survey of research firms that cover Biohaven Pharmaceutical.
Biohaven Pharmaceutical (NYSE:BHVN) last issued its earnings results on Friday, November 1st. The company reported ($2.04) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.57) by ($0.47).
Shares of Biohaven Pharmaceutical stock traded up $0.53 during trading hours on Friday, hitting $52.09. The company’s stock had a trading volume of 375,967 shares, compared to its average volume of 496,758. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of -8.47 and a beta of 0.34. Biohaven Pharmaceutical has a twelve month low of $29.17 and a twelve month high of $67.86. The firm has a fifty day moving average of $45.76 and a 200-day moving average of $47.45.
In other news, insider Elyse Stock sold 17,700 shares of the company’s stock in a transaction on Friday, October 18th. The stock was sold at an average price of $45.07, for a total transaction of $797,739.00. Following the sale, the insider now owns 17,700 shares of the company’s stock, valued at $797,739. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Eric Aguiar sold 10,000 shares of the stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $45.00, for a total value of $450,000.00. The disclosure for this sale can be found here. Insiders have sold a total of 28,500 shares of company stock valued at $1,283,747 over the last 90 days. 23.90% of the stock is currently owned by company insiders.
Several institutional investors have recently made changes to their positions in BHVN. Nisa Investment Advisors LLC raised its holdings in Biohaven Pharmaceutical by 511.1% in the third quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $46,000 after acquiring an additional 920 shares in the last quarter. Tower Research Capital LLC TRC acquired a new stake in shares of Biohaven Pharmaceutical in the 2nd quarter valued at $65,000. Aperio Group LLC purchased a new stake in shares of Biohaven Pharmaceutical during the 2nd quarter worth $71,000. Glen Harbor Capital Management LLC lifted its position in shares of Biohaven Pharmaceutical by 165.9% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,744 shares of the company’s stock worth $76,000 after purchasing an additional 1,088 shares during the last quarter. Finally, Canton Hathaway LLC acquired a new position in shares of Biohaven Pharmaceutical during the third quarter worth $83,000. 90.39% of the stock is owned by institutional investors and hedge funds.
Biohaven Pharmaceutical Company Profile
Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.
See Also: Which market index is the best?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.